ARCT - Arcturus Therapeutics Holdings Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States

Full Time Employees72

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph E. Payne M.Sc.Founder, Pres, CEO & Director2.05MN/A1972
Dr. Padmanabh ChivukulaFounder, Chief Scientific Officer, COO & Sec.948.31kN/A1979
Mr. Andrew H. SassineChief Financial Officer349.02kN/A1964
Mr. J.P. HeadleyAssociate Director of Accounting & OperationsN/AN/AN/A
Ms. Neda SafarzadehDirector and Head of Investor Relations/PR & MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs to treat ornithine transcarbamylase deficiency, cystic fibrosis, glycogen storage disease type 3, hepatitis B, and non-alcoholic steatohepatitis. Its RNA therapeutics platforms could be applied toward various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 154 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. The company develops RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Arcturus Therapeutics Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.